Last reviewed · How we verify
olmesartan medoxomil and a diuretic
Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while the diuretic component enhances sodium and water excretion to further reduce fluid volume and blood pressure.
Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while the diuretic component enhances sodium and water excretion to further reduce fluid volume and blood pressure. Used for Hypertension.
At a glance
| Generic name | olmesartan medoxomil and a diuretic |
|---|---|
| Sponsor | Daiichi Sankyo Co., Ltd. |
| Drug class | Angiotensin II receptor blocker (ARB) + diuretic combination |
| Target | AT1 receptor (angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing vasoconstriction and aldosterone secretion. The addition of a diuretic (typically hydrochlorothiazide) increases renal sodium and water excretion, reducing circulating blood volume. Together, these complementary mechanisms provide synergistic antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Hyperkalemia
- Renal impairment
- Hypotension
- Hypokalemia (diuretic component)
Key clinical trials
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- MRA and ARB Treatment in Screening of Primary Aldosteronism
- Use of Impedance Cardiography and Applanation Tonometry for Prediction of the Antihypertensive Effect of Two Drugs (NA)
- Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension (PHASE4)
- Renin Profiling in Selection of Initial Antihypertensive Drug (NA)
- Combination Pill of Losartan Potassium and Hydrochlorothiazide for Improvement of Medication Compliance Trial (PHASE3)
- The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- olmesartan medoxomil and a diuretic CI brief — competitive landscape report
- olmesartan medoxomil and a diuretic updates RSS · CI watch RSS
- Daiichi Sankyo Co., Ltd. portfolio CI